Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, and Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan.
J Neuroophthalmol. 2020 Mar;40(1):74-83. doi: 10.1097/WNO.0000000000000890.
Thyroid-associated ophthalmopathy (TAO) is an autoimmune component of Graves' disease for which no currently available medical therapy provides reliable and safe benefit. Based on insights generated experimentally over the past several decades, the insulin-like growth factor-I receptor (IGF-IR) has been implicated in the pathogenesis of TAO. Furthermore, an IGF-IR inhibitor, teprotumumab, has emerged from 2 clinical trials as a promising treatment for active, moderate to severe TAO. This brief review intends to provide an overview of the rationale underlying the development of teprotumumab for this disease. It is possible that teprotumumab will soon take its place in our therapeutic armamentarium for active TAO.
甲状腺相关眼病（TAO）是 Graves 病的自身免疫成分，目前尚无可用的医学治疗方法能提供可靠和安全的益处。基于过去几十年的实验研究结果，胰岛素样生长因子-I 受体（IGF-IR）已被认为与 TAO 的发病机制有关。此外，一种 IGF-IR 抑制剂——特普利单抗，已在两项临床试验中崭露头角，成为治疗活动性、中重度 TAO 的有前途的治疗方法。这篇简要综述旨在概述开发特普利单抗治疗这种疾病的基本原理。特普利单抗很可能很快就会成为我们治疗活动性 TAO 的治疗武器之一。
